ArticleMedical hypotheses2020
May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review.Prostate cancer and prostatic diseases · 2022Pooled it
- The Experience of SARS-CoV-2 in Patients with Benign Prostatic Hyperplasia: Is There Any Correlation between Them?Maedica · 2025Review
- Androgenetic alopecia and COVID-19: A review of the hypothetical role of androgens.Dermatologic therapy · 2021Review
- Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial.Medical journal of the Islamic Republic of Iran · 2021Article
- Testosterone in COVID-19: An Adversary Bane or Comrade Boon.Frontiers in cellular and infection microbiology · 2021Review
- Testosterone in COVID-19 - Foe, Friend or Fatal Victim?European endocrinology · 2020Article
- Effects of 5-alpha reductase inhibitors on lung function: A reason for discontinuation during COVID-19 pandemic?Dermatologic therapy · 2020Article
- Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 pandemic is a major challenge for global and national healthcare providers. Number of new cases is continuously increasing with an emerging trend showing worse prognosis in males in comparison to females. Based on this observation, our proposed hypothesis is that 5-alpha-reductase inhibitors, that are commonly used for BPH treatment, may be one of the factors contributing to poorer prognosis in males.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.